CAS: 10576-12-2; Ethyl N-Hydroxyacetimidate

相似化合物

2208-07-3 20703-42-8

上下游产品

CAS号1000-84-6 乙基乙酰亚胺盐酸盐 | CAS号2208-07-3 乙基乙酰亚胺盐酸盐 | CAS号64-17-5 乙醇 | CAS号75-05-8 乙腈 | CAS号107448-74-8 ethyl N-[1-(hyd... | CAS号38202-27-6 O-(2,4,6-三甲基苯磺酰... | CAS号54322-32-6 N-(2,4-二硝基苯氧基)乙亚氨酸乙酯 | CAS号7803-49-8 羟胺 | CAS号35657-45-5 (1-ethoxyethyli... | CAS号35657-44-4 (1-ethoxyethyli... | CAS号648441-30-9 N-hydroxy-N'-[1... | CAS号80538-49-4 (1-ethoxyethyli... | CAS号83077-00-3 ethyl N-(4-nitr... | CAS号89232-68-8 ethyl N-(3,4-di...

1-乙氧基乙基亚基氯化铵置于盐酸羟胺,Potassium Carbonate体系中,用 乙醚,水 用作溶剂,化学反应 0.5H,以65%的收率获得乙酰羟肟酸乙酯
参考文献:α-氯亚硝基醚的diels-Alder反应中的非对映选择性和反应性
标题:α-氯亚硝基醚的diels-Alder反应中的非对映选择性和反应性
摘要:通过x射线晶体学分析,确定了由氢氧内酯2和次氯酸叔丁酯(89%)获得的α-氯亚硝基醚1的结构.在[4 + 2]环加成的1与二烯3和8-11导致ñ-未被取代的3,6-二氢-2-ħ-1,2-恶嗪6和12-16高对映体过量(表1) .由于额外的α-烷氧基,2的反应性远远优于已知的α-氯亚硝基链烷烃之一.的反应构象从x射线分析以及环加成的高非对映选择性推论出1.α-烷氧基的重要性由外消旋α-Chloronitroso的类似的反应性证实醚25-27,其从该hydroximo制备醚28-30和叔丁基次氯酸盐.
Doi:10.1002/hlca.19860690522

专利信息

专利号:US-8779201-B2
优先权日:2007-10-02
标题 :Process for preparing benzofurans
发明人：EKLUND LARS
权利人:CAMBREX KARLSKOGA AB
摘要:There is provided a process for the preparation of a compound of formula (I), wherein R 1 , R 2 , R 3 , R 4 , X and Y are as described in the description. Such compounds may, for example, be useful intermediates in the synthesis of drugs such as Dronedarone.

专利号:US-2023219994-A1
优先权日:2019-08-14
标 题:Modified nucleoside and synthesis method therefor
发明人：CAI YUNSONG; LI HANGWEN; LIU LIANXIAO; LI NING
权利人:STEMIRNA THERAPEUTICS CO LTD
摘要:A modified cytidine compound, that is, an aminooxy group is modified at the 4-position of a cytidine pyrimidine ring to produce derivative cytidine and nucleic acid containing the derivative cytidine, such as RNA. The expression level of the nucleic acid containing the modified cytidine, in particular mRNA, in the body is significantly improved.

专利号:CN-112745244-B
优先权日:2019-10-30
标 题 :A kind of intermediate of siponimod and its synthesis method

专利号:US-9663511-B2
优先权日:2012-03-26
标题:Sphingosine 1-phosphate receptor antagonists
发明人：SWENSON ROLF E
权利人:ARROYO BIOSCIENCES LLC
摘要:The present invention relates to sphingosine-1-phosphate (S1P) receptors and compounds of the general formula: n nthat are useful in the treatment and prevention of conditions associated with such receptors. More specifically, the present invention relates to the synthesis and use of sphingosine 1-phosphate receptor 2 (S1P 2 ) antagonists that are useful in the treatment of cancer, atherosclerosis, diabetic retinopathy, and other inflammatory diseases. Among these inflammatory diseases that could be treated with these S1P 2 antagonist are those characterized by fibrosis including chronic lung disease, chronic kidney and liver disease, chronic heart disease, and skin diseases such as sclerosis/scleroderma. The S1P 2 antagonists can also be used in the treatment of glioblastoma multiforme (brain cancer), pediatric neuroblastoma, and other cancers.

专利号:CN-112745244-A
优先权日:2019-10-30
标题 :A kind of intermediate of simpomod and its synthesis method